StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
PLXBullishEarningsnews
High materiality9/10

Protalix Q2 2026: Elfabrio growth and IP moat underpin upside

Aug 12, 2026, 6:54 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

stronger revenues, confirmed guidance, IP extensions, and a cash-rich balance sheet support higher valuation; near-term upside potential from PRX-115 topline and Elfabrio moat.

AI summary

What happened, with direct paths to the underlying reporting

Protalix BioTherapeutics posted strong Q2 2026 results, with revenues from selling goods of $19.8 million and year-to-date revenue of $53.6 million, aided by Elfabrio sales and a $25 million milestone from Chiesi. The company also reported net income of $22.1 million year-to-date and a cash balance of $40.7 million with no debt, while reaffirming 2026 guidance. Key near-term catalysts include the PRX-115 Phase 2 RELEASE topline due in 2H 2027 and ongoing IP protections that extend Elfabrio through 2035.

  • Q2 2026 revenues from selling goods rose to $19.8M. Elfabrio drove growth globally.
  • YTD revenue $53.6M. Includes $25M Chiesi milestone.
  • YTD net income $22.1M. Cash $40.7M.
  • Elfabrio patent term extension to 2035; Korea orphan designation.
  • PRX-115 RELEASE Phase 2 enrollment continues; topline in 2H 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event